Idelalisib (CAL-101, GS-1101)

目录号:S2226

Idelalisib (CAL-101, GS-1101) Chemical Structure

Molecular Weight(MW): 415.42

Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂,在无细胞试验中IC50为 2.5 nM;对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍,对p110δ的选择性是对 C2β,hVPS34,DNA-PK 和 mTOR的400到4000倍。

规格 价格 库存 购买数量  
RMB 1279.19 现货
RMB 972.85 现货
RMB 3867.24 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户购买Selleck的此次产品后发表的文献31篇:

客户使用该产品的5个实验数据:

  • Invasive migration of RA FLS was analyzed through growth factor–reduced Matrigel-coated transwell inserts in the presence or absence of 1 µM INK007, 5 µM CAL-101, or 0.3 µM IPI-145, or 0.3 µM GDC-0941 inhibitors or DMSO. Cells were allowed to invade through Matrigel toward PDGF-BB (25 ng/ml) containing media for 24 h and were fixed and stained with Hemacolor staining kit.

    J Immunol, 2014, 192(5): 2063-70 . Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    Ppp2r1afl/fl BCR-ABL1 B-ALL cells transduced with 4-OHT-inducible Cre-ERT2 (Cre) or ERT2-vector (EV) were treated with 4-OHT for 3 days and cell lysates were studied by phospho-protein array analysis. Ppp2r1afl/fl BCR-ABL1 ALL cells were transduced with 4-OHT-inducible Cre or EV control and incubated in the presence of the small molecule signaling inhibitor idelalisib (32 μmol/L; C). Percentages of GFP+ cells were measured by flow cytometry at the times indicated following 4-OHT-treatment. Data are shown as mean ± standard deviation (SD) and representative of at least three independent experiments.

    Cell, 2018, 173(2):470-484. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • 293T cells were transfected with HA-tagged Fbxo45. At 48 h after transfection, cells were treated with AKT inhibitor (CAL-101; 10 uM, 4 h), cell extracts from the cytoplasm or nuclei were subjected to IP with anti-HA resin followed by western blot analysis with indicated antibodies.

    Cell Death Differ 2014 21(10), 1535-45. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

    Isoform-selective PI3K inhibitors blocked PI3K signaling in corresponding Rh30-Myr-p110 cells. Rh30-Myr-p110s cells were cultured in serum-free medium for 12 h, and then exposed to CAL-101 at indicated concentrations for additional 1 h. The cells were collected to detect the level of phosphorylated and total Akt. β-Actin was served as loading control.

    Acta Pharmacol Sin 2013 34(9),1201-7. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

  • After starved in serum-free medium for 24 h,A549 cells incubated with the indicated concentrations of CAL-101 for 3 h,followed by 20-minute stimolation of 100ng/ml EGF.

    Dr. Zhang of Tianjin Medical University. Idelalisib (CAL-101, GS-1101) purchased from Selleck.

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Idelalisib (CAL-101, GS-1101) 是选择性p110δ抑制剂,在无细胞试验中IC50为 2.5 nM;对 p110δ 表现出的选择性是对 p110α/β/γ 的 40 到 300 倍,对p110δ的选择性是对 C2β,hVPS34,DNA-PK 和 mTOR的400到4000倍。
特性 Calistoga 暗示 CAL-101治疗血液恶性肿瘤可能有更广泛的应用价值。
靶点
p110δ [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
2.5 nM 89 nM
体外研究

CAL-101 对p110α, p110β,和p110γ作用效果不大。CAL-101作用于原代嗜碱细胞特定阻断FcϵR1 p110δ调节的 CD63表达,EC50 为8 nM。与急性髓性白血病(AML) 和骨髓增生性肿瘤(MPN) 细胞相比,CAL-101 作用于B-cell急性淋巴细胞白血病(B-ALL)和慢性淋巴细胞白血病(CLL) 细胞时显示更强的活性。CAL-101 作用于SU-DHL-5, KARPAS-422 和CCRF-SB细胞,降低pAktS473, pAktT308, 和下游靶点S6, EC50为0.1到1.0 μM。 [1] CAL-101 作用于CLL细胞,诱导选择性细胞毒性,不是通过突变状态或间期细胞遗传学,主要通过caspase依赖机制。与正常B细胞相比,CAL-101作用于CLL 细胞优先产生细胞毒性,和LY294002相比,作用于其他造血细胞不会产生毒性。CAL-101 作用于T 细胞和天然杀伤细胞 缺乏直接的细胞毒性潜能。CAL-101抑制炎症细胞因子的产生,比如 IL-6, IL-10, TNF-α,和IFN-γ,且激活诱导的细胞因子,如CD40L。CAL-101 也抗CD40L调节的CLL细胞存活。[2] CAL-101 作用于L1236和L591细胞, 诱导细胞在G1期积累,在S期下降,说明 CAL-101可以作为治疗霍杰金淋巴瘤(HL)的一种新策略。[3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MEC1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fPdWROW09? NIfjbYpKSzVyPUKwMlQh|ryP M3TEW|I2QTl7M{Wy
CLL PBMCs MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4P6RWROW09? NHrHcHNKSzVyPUKuPUBvVQ>? MkHzNlU6OTd{Nke=
U266 NFf1bHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUi0NEDPxE1? NVqyeHc6PDhiaB?= M3PGTlc6NjVnIHnubIljcXSrb36gdoF1\Q>? MlLFNlU{Ozl|M{K=
K562 NF7YUolHfW6ldHnvckBCe3OjeR?= NVvXS2s2OSEQvF2= MUezJIg> NUW0SIVsUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u NIn0[2wzPTBzNEe3OS=>
K562 NEjLbZlHfW6ldHnvckBCe3OjeR?= NUTjVmpOOSEQvF2= NGDFWpc{KGh? NXrI[JkyUW6qaXLpeIlwdiCxZjDQO|BUPkticHjvd5Bpd3K7bHH0bY9v MnvyNlUxOTR5N{W=
K562 MXHGeY5kfGmxbjDBd5NigQ>? MoLUNUDPxE1? MWmzJIg> M1rhZ2lvcGmkaYTpc44hd2ZiR2PLN{BxcG:|cHjvdplt[XSrb36= MVGyOVAyPDd5NR?=
K562 NX\YdVQyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWOxJO69VQ>? NFPGUFg4OiCq NW\IR2dyUW6qaXLpeIlwdiCxZjDwdo9tcW[ncnH0bY9v Mn7qNlUxOTR5N{W=
Primary AML cell MlP6SpVv[3Srb36gRZN{[Xl? MnPjNUDPxE1? NV\XNHJTOyCq NHn6U|JKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36= MWCyOVAyPDd5NR?=
Primary AML cell M37USGZ2dmO2aX;uJGF{e2G7 MY[xJO69VQ>? NXzQWGhiOyCq M{fxe2lvcGmkaYTpc44hd2ZiUEewV|ZMKHCqb4PwbI9zgWyjdHnvci=> MYiyOVAyPDd5NR?=
Primary AML cell NXnsOXpsTnWwY4Tpc44hSXO|YYm= NUDUbHNbOSEQvF2= NWnCN4Y2OyCq M3TEcmlvcGmkaYTpc44hd2ZiR2PLN{BxcG:|cHjvdplt[XSrb36= MmfhNlUxOTR5N{W=
Primary AML cell MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DU[lEh|ryP M2fLSFMhcA>? NID2UoZUfXCycnXzd4lwdiCxZjDyVm5CKHO7boTo[ZNqew>? M3fnTVI2ODF2N{e1
Microglia NHPWOoZHfW6ldHnvckBCe3OjeR?= NGDtRno2KM7:TR?= MnyxNVAhcA>? NXzkXpRuTE2VTx?= MVXE[YNz\WG|ZTDv[kBVVk[jIIPlZ5JmfGmxbjDmdo9uKEySUz3zeIlufWyjdHXkJEBxOTFyzsTEPVExSS:GOUGwRUBucWO{b3fsbYE> MnPwNlQ3OjV4OES=
Primary CLL cell NUTUT4NYTnWwY4Tpc44hSXO|YYm= M1PUNVEh|ryP MVyxOUBucW5? NE\S[|BFVVOR NIXKZ3RDdG:la4OgRmNTNWmwZIXj[YQhVEOSMTDz[ZJqdmVvNTDhZ5RqfmG2aX;u NIXTS|EzPDByOUKzNy=>
JEKO-1 MXHGeY5kfGmxbjDBd5NigQ>? MkDzNUDPxE1? M2TUTlczKGh? M124UWlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDpckBK\01vc4TpcZVt[XSnZDDKSWtQNTF? NWK0W2JbOjN|NEG1OFE>
Granta-519 MljUSpVv[3Srb36gRZN{[Xl? M{HYWVEh|ryP NXHQbXZFOiCq MYDJcohq[mm2aX;uJI9nKEGtdDj0N|A5MSCyaH;zdIhwenmuYYTpc44> M{izdlI{OzRzNUSx
Granta-519 M2D5UWZ2dmO2aX;uJGF{e2G7 NWLXV5pLOSEQvF2= M2HKU|IhcA>? MYPJcohq[mm2aX;uJI9nKEGtdDjzOFc{MSCyaH;zdIhwenmuYYTpc44> NYLIXJVUOjN|NEG1OFE>
JEKO-1 MkTES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEPRXIgyOCEQvF2= MmTEO|IhcA>? NGXLcmRKdmirYnn0bY9vKG:oIIDyc4xq\mW{YYTpc44he2yrZ3j0cJk> NW\j[GI1OjN|NEG1OFE>
JEKO-1 M1q1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfseZY2KM7:TR?= NH\uRmQ4OiCq NYTKXphk\G:nczDuc5QhcW6mdXPlJINmdGxiY4njcIUh[XK{ZYP0JI9zKGGyb4D0c5Nqew>? MoHONlM3PzZ{MkC=
MAVER-1 NFPpVHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTWOUDPxE1? NHPUS|g4OiCq NXT3SJF2\G:nczDuc5QhcW6mdXPlJINmdGxiY4njcIUh[XK{ZYP0JI9zKGGyb4D0c5Nqew>? NULa[lFwOjN4N{[yNlA>
MINO NUTTPZhnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\DeoNRPSEQvF2= M{\6V|czKGh? NF\GZVJld2W|IH7veEBqdmS3Y3WgZ4VtdCCleXPs[UBienKnc4Sgc5Ih[XCxcITvd4l{ M4rrZVI{Pjd4MkKw
SP53 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4[1d|AvOSEQvF2= MYS3NkBp M3TmfoRw\XNibn;0JIlv\HWlZTDj[YxtKGO7Y3zlJIFzemW|dDDvdkBieG:ydH;zbZM> NUXtNWs{OjN4N{[yNlA>
HH MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUKxNEDPxE1? M3jRbVczKGh? M{S1PWROW09? M1z2fGlv\HWldHnvckBw\iCjcH;weI9{cXNic3zp[4h1dHl? MVeyNlgxOTl3OR?=
Myla MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV6xNEDPxE1? MkS3O|IhcA>? NVvDOGVyTE2VTx?= NUToXlA3\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> NWizNG5rOjJ6MEG5OVk>
SR786 M2jLWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjTd3kyOCEQvF2= Mor5O|IhcA>? MWXEUXNQ NVPwb5Bu\G:nczDuc5QhcW6mdXPlJIFxd3C2b4Ppdy=> NUjWdJJOOjJ6MEG5OVk>
HuT78 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGGyXXoyOCEQvF2= M3v3eVczKGh? M2O1NGROW09? MnPP[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= M3SxNFIzQDBzOUW5
MJ MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHaSIlEOTBizszN NWjm[2c4PzJiaB?= M2fLT2ROW09? MnPn[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= M2TNW|IzQDBzOUW5
DERL7 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXuxNEDPxE1? NFy3N5g4OiCq MnfCSG1UVw>? MlGx[I9meyCwb4SgbY5lfWOnIHHwc5B1d3Orcx?= NHn5b2QzOjhyMUm1PS=>
L1236 M1LQZmZ2dmO2aX;uJGF{e2G7 M2XRPFExKM7:TR?= M4rLOFIhcA>? MWDJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? MkG4NlIzOTB6N{e=
L428 NF3QfWxHfW6ldHnvckBCe3OjeR?= MUexNEDPxE1? MmrZNkBp M2\ISGlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbh?= MkfXNlIzOTB6N{e=
L591 Mn61SpVv[3Srb36gRZN{[Xl? MUOxNEDPxE1? MkHJNkBp NYG0TJI4UW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;u NXu2UoxpOjJ{MUC4O|c>
KMH-2 M4XEOGZ2dmO2aX;uJGF{e2G7 NEnsUWoyOCEQvF2= MWWyJIg> MVfJcohq[mm2aX;uJI9nKEGtdDDwbI9{eGixconsZZRqd25? NU\UZnN6OjJ{MUC4O|c>
L1236 NFLwdm5HfW6ldHnvckBCe3OjeR?= MVS1JO69VQ>? Ml7nNlQhcA>? M{\PN2Jtd2OtczDz[YNz\XSrb36gc4YhfGinIFPDUFU> MlPsNlIzOTB6N{e=
L591 MX3GeY5kfGmxbjDBd5NigQ>? NG\yZoE2KM7:TR?= MWWyOEBp M{\pNmJtd2OtczDz[YNz\XSrb36gc4YhfGinIFPDUFU> Mm[zNlIzOTB6N{e=
L1236 NEjQ[|JCeG:ydH;zbZMhSXO|YYm= NX\WW3Z{PSEQvF2= M1z2OlI1KGh? NIDTXlJKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| NFy1[W8zOjJzMEi3Oy=>
L591 MXjBdI9xfG:|aYOgRZN{[Xl? NYHiZ5NIPSEQvF2= NHTLSY0zPCCq MWfJcoR2[3Srb36gc4Yh[XCxcITvd4l{ MY[yNlIyODh5Nx?=
U-87MG MYXGeY5kfGmxbjDBd5NigQ>? MWGxNFAhdk1? M4W5VFI1KGh? M3TsVGROW09? NUnpVZg4UW6qaXLpeIlwdiCxZjCgZ4VtdCCvaXfyZZRqd25? M4TNdFIzODd7NkC5
SW1783 NYO2WJk{TnWwY4Tpc44hSXO|YYm= MYWxNFAhdk1? MoLKNlQhcA>? M13vO2ROW09? MkP1TY5pcWKrdHnvckBw\iBiY3XscEBucWe{YYTpc44> NIjJV5QzOjB5OU[wPS=>
U-87MG NHTTWoxHfW6ldHnvckBCe3OjeR?= NHXVeIU2KM7:TR?= MlTMNlQhcA>? NVSyXmp[TE2VTx?= NFP1dmRKdmirYnn0bY9vKG:oIFHreEBxcG:|cHjvdplt[XSrb36gd5Vje3SjboTpZYxtgQ>? MkLYNlIxPzl4MEm=
SW1783 MUDGeY5kfGmxbjDBd5NigQ>? MY[1JO69VQ>? NFjVPVAzPCCq NGXuSWJFVVOR NVHTXnUzUW6qaXLpeIlwdiCxZjDBb5QheGixc4Doc5J6dGG2aX;uJJN2[nO2YX70bYFtdHl? M1yzXFIzODd7NkC5
U-373MG MmXVSpVv[3Srb36gRZN{[Xl? M2L2eFUh|ryP M{TGU|I1KGh? M3[zNGROW09? M3iyRmlvcGmkaYTpc44hd2ZiQXv0JJBpd3OyaH;yfYxifGmxbjDzeYJ{fGGwdHnhcIx6 NYnSPZA5OjJyN{m2NFk>
SK-MG3 MknISpVv[3Srb36gRZN{[Xl? M37melUh|ryP NEj3VoQzPCCq M1vDR2ROW09? MkDxTY5pcWKrdHnvckBw\iCDa4SgdIhwe3Cqb4L5cIF1cW:wIIP1ZpN1[W62aXHscJk> M{j6NFIzODd7NkC5
SU-DHL-5 Mk[ySpVv[3Srb36gRZN{[Xl? MWCxJO69VQ>? NYCxO|FHOjRiaB?= NIfSWI9FVVOR NH\Sc5lKdmS3Y4Tpc44hd2ZiYYDvdJRwe2m| MWeyNFk2QTZyNh?=
WSU-NHL NXnWflhrTnWwY4Tpc44hSXO|YYm= NH3lRmMyKM7:TR?= MXyyOEBp M2X6eWROW09? MXfJcoR2[3Srb36gc4Yh[XCxcITvd4l{ NV3kSphQOjB7NUm2NFY>
CCRF-SB M2TOO2Z2dmO2aX;uJGF{e2G7 MkfJNUDPxE1? M3zrdlI1KGh? NX3IeJBjTE2VTx?= M2i2OGlv\HWldHnvckBw\iCjcH;weI9{cXN? NFTJeIQzODl3OU[wOi=>
INA-6 MlP6SpVv[3Srb36gRZN{[Xl? NYjpbYFMPSEQvF2= M2[1eVYhcA>? MW\Jcohq[mm2aX;uJI9nKFCLM1uvRYt1KGGwZDDFVmsheGG2aIfhfS=> MlvwNlA2ODVzNUi=
LB NUPrflQ{TnWwY4Tpc44hSXO|YYm= NGjycXY2KM7:TR?= M{nWVFYhcA>? MlLGTY5pcWKrdHnvckBw\iCSSUTLM2FsfCCjbnSgSXJMKHCjdHj3ZZk> MlPYNlA2ODVzNUi=

... Click to View More Cell Line Experimental Data

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
+ 展开

PI3K实验:

用全CLL和正常B细胞溶解物进行PI3K实验。 进行PI3K ELISA 实验。全细胞抽提物加到PI(4,5)P2 底物和反应 buffer(包含 ATP)的混合物中,在室温下温育。加入 PI(3,4,5)P3 探测器和 EDTA混合,反应终止,在室温下温育1小时。混合物转移到PI3K ELISA板上,再温育1小时。 冲洗反应板,然后和第二探测器再温育30分钟。再次冲洗反应板, 加入3,3′,5,5′-四甲基联苯胺溶液 ,反应5分钟,加入H2SO4 终止反应。在450纳米处读数。
细胞实验:[2]
+ 展开
  • Cell lines: CLL B 细胞或健康志愿者的T细胞或NK细胞
  • Concentrations: 0.01-100 μM
  • Incubation Time: 48小时
  • Method: 进行MTT实验测定细胞毒性。1×105个细胞和CAL-101一起温育。加入MTT试剂, 再次温育20小时,然后用溶于PBS的硫酸鱼精蛋白冲洗。加入DMSO, 用分光光度计在540纳米处测定吸光度。使用膜联蛋白/PI液式细胞计检查在不同时间点测定细胞存活力,分析数据。每个样本至少计数104个细胞。以全部阳性细胞与未处理细胞之比百分数的形式来表示实验结果。加入100 μM Z-VAD检测caspase-依赖的细胞凋亡。加入 1 μg/mL CD40L, 800 U/mL IL-4, 50 ng/mL BAFF, 20 ng/mL TNF-α测定存活信号, 或者共培养在纤连蛋白或 HS-5 细胞系基质包被的板上。 基质共培养 在75cm2培养瓶 (80%-100% 融合率) 培养24 小时,然后加入CLL细胞。
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 83 mg/mL warmed (199.79 mM)
Ethanol 23 mg/mL (55.36 mM)
Water Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
30% PEG 400 (dissolve first)+0.5% Tween 80+5% Propylene glycol
30mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 415.42
化学式

C22H18FN7O

CAS号 870281-82-6
稳定性 powder
in solvent
别名 N/A

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03576443 Recruiting Diffuse Large B Cell Lymphoma Nordic Lymphoma Group July 7 2017 Phase 2
NCT02962401 Active not recruiting Waldenstrom Macroglobulinemia French Innovative Leukemia Organisation March 7 2017 Phase 2
NCT02044822 Terminated B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion Gilead Sciences August 6 2014 Phase 2
NCT02436135 Completed Myelofibrosis Gilead Sciences June 5 2015 Phase 1
NCT01980888 Terminated Chronic Lymphocytic Leukemia Gilead Sciences February 5 2014 Phase 3
NCT02739360 Completed Lymphoid Malignancies Gilead Sciences May 4 2016 Phase 4

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    What is the recommended dose of CAL-101 and the route of administration for mouse studies?

  • 回答:

    According to the following paper, S2226 can be used by I.V. administration at the concentration of 40 mg/kg. https://www.ncbi.nlm.nih.gov/pubmed/24625684

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)供应商 | 采购Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)价格 | Idelalisib (CAL-101, GS-1101)生产 | 订购Idelalisib (CAL-101, GS-1101) | Idelalisib (CAL-101, GS-1101)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID